AbbVie Soars 3.4% on Strong Q1 Earnings

AbbVie's stock rose 3.4% in pre-market trading on April 25, 2025, driven by strong first-quarter financial results.

AbbVie reported first-quarter 2025 revenue of $13.34 billion, surpassing market expectations of $12.91 billion and marking a 9% increase from the same period last year. The company's earnings per share (EPS) on a GAAP basis were $0.72, a decrease of 6.5% year-over-year, while adjusted EPS increased by 6.5% to $2.46. This positive performance was largely attributed to the robust sales of newer drugs such as Skyrizi and Rinvoq, which offset the decline in sales of Humira due to competition from biosimilars.

Despite the challenges posed by the loss of exclusivity for Humira, AbbVie's strategic focus on its immunology portfolio has paid off. The company's newer drugs, Skyrizi and Rinvoq, have shown remarkable growth, with combined sales exceeding $17 billion in 2024. Skyrizi, in particular, has emerged as a key growth driver, with sales expected to reach $20 billion by 2027, matching the peak sales of Humira.

Looking ahead, AbbVie has raised its full-year 2025 adjusted EPS guidance to a range of $12.09 to $12.29, up from the previous estimate of $11.99. The company's strong performance in the first quarter, coupled with its strategic investments in new therapies, positions it well for continued growth in the coming years.